The FDA Just Voted on BPC-157. It Was Close.

On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee voted eight to six, with one abstention, to recommend adding BPC-157 to the 503A bulks list. A recommendation, not an approval, and a margin that tells you how divided the room was.Dr. Sasha Rose and Colin Renaud, PA-C walk through what BPC-157 actually is, where the research genuinely sits, and why the gap between how badly people want it and how little human evidence exists is the whole story. They cover what the 503A bulks list is, why ulcerative colitis was the use flagged for review, and why human clinical trials on this are so hard to run.They are also direct about the parts nobody likes talking about: the quality and purity problem with unregulated online vendors, the exaggerated claims circulating on social media, and the fact that no peptide substitutes for diet and sleep.For educational purposes only. Not personal medical advice.